MARKET

RTTR

RTTR

Ritter Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3176
-0.0124
-3.76%
After Hours: 0.3177 +0.0001 +0.03% 19:42 03/27 EDT
OPEN
0.3100
PREV CLOSE
0.3300
HIGH
0.3498
LOW
0.3000
VOLUME
5.60M
TURNOVER
--
52 WEEK HIGH
1.270
52 WEEK LOW
0.1500
MARKET CAP
3.23M
P/E (TTM)
-0.1179
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RTTR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RTTR stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.

EPS

RTTR News

More
  • Mid-Morning Market Update: Markets Open Lower As Coronavirus Spreads; Foot Locker Posts Mixed Q4 Results
  • Benzinga · 02/28 15:09
  • Ritter Pharma to merger with Qualigen; shares up 28%
  • seekingalpha · 01/21 20:03
  • Ritter Pharma, Qualigen To Merge; Pre-Merger Ritter Shareholders To Own ~7.5% Of Combined Co.
  • Benzinga · 01/21 14:18
  • Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
  • GlobeNewswire · 01/21 14:15

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About RTTR

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient's health. The Company's compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.
More

Webull offers kinds of Ritter Pharmaceuticals Inc stock information, including NASDAQ:RTTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RTTR stock news, and many more online research tools to help you make informed decisions.